Amgen (AMGN) reported fourth-quarter 2023 adjusted earnings of $4.71 per share, which beat the Zacks Consensus Estimate of $4.66. Earnings rose 15% year over year on higher revenues, which were partially offset by higher operating costs and higher interest expenses.Total revenues of $8.2 billion marginally beat the Zacks Consensus Estimate of $8.16 billion. Total revenues rose 20% year over year, driven by higher product sales.Total product revenues increased 20% from the year-ago quarter to $7.83 billion ( ...

Amgen (AMGN) reported $8.2 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 19.8%. EPS of $4.71 for the same period compares to $4.09 a year ago.The reported revenue represents a surprise of +1.00% over the Zacks Consensus Estimate of $8.11 billion. With the consensus EPS estimate being $4.66, the EPS surprise was +1.07%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expe ...

Amgen (AMGN) came out with quarterly earnings of $4.71 per share, beating the Zacks Consensus Estimate of $4.66 per share. This compares to earnings of $4.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.07%. A quarter ago, it was expected that this world's largest biotech drugmaker would post earnings of $4.65 per share when it actually produced earnings of $4.96, delivering a surprise of 6.67%.Over the last four quarters ...

Amgen Inc. on Tuesday reported fourth-quarter profits and sales that topped analysts’ expectations even as revenues dropped for one of its top sellers, the rheumatoid-arthritis drug Enbrel. The biotech company reported fourth-quarter net income of $767 million, or $1.42 per share, versus $1.62 billion, or $3.00 per share, in the year-earlier period. Adjusted per-share earnings of $4.71 topped the FactSet consensus of $4.59. Revenues totaled $8.196 billion in the quarter, up from $6.839 billion a year earlie ...

While the Nasdaq exchange and S&P 500 grabbed the headlines because of the massive run-up by the so-called Magnificent 7 stocks, the Dow Jones Industrial Average plodded on with its Dow stocks to buy. It recorded its own double-digit gains for the year, and ended 2023 at an all-time high. This was not too shabby for 30 stalwart stocks. For more 125 years, investors have turned to the Dow to measure the health of the stock market and the direction of the United States economy. Although it’s still called the ...

Analysts on Wall Street project that Amgen (AMGN) will announce quarterly earnings of $4.69 per share in its forthcoming report, representing an increase of 14.7% year over year. Revenues are projected to reach $8.12 billion, increasing 18.7% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.P ...

The market expects Amgen (AMGN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Amgen (AMGN) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.This world's largest biotech drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 9.64%.For the last reported quar ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this world's largest biotech drugmaker have returned +8.3%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Amgen falls in, has lost 0.2%. The key question now is: What could be the stock's future direction?W ...

We expect Amgen (AMGN) to beat expectations when it reports fourth-quarter and full-year 2023 results on Feb 6, after market close. In the last reported quarter, the company delivered an earnings surprise of 6.67%.Factors to ConsiderAmgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Prolia and Blincyto, among others. However, the prices of most products are expected to have declined.The Zacks Consensus Estimate for Prolia, Repatha, Evenity and B ...